高膽固醇不只傷心血管！職業醫學告訴你也可能增加腕隧道症候群風險

《高膽固醇血症與腕隧道症候群關聯性的統合分析。

林彥廷醫師，中華職業醫學雜誌 32(3)：211-220, 2025

現代人因飲食西化、工作型態改變以及缺乏運動，高膽固醇已成為常見的健康問題。許多人知道高膽固醇會增加心肌梗塞、中風等心血管疾病風險，但其實它對神經健康也可能造成影響。近年研究發現，高膽固醇與「腕隧道症候群」之間存在明顯關聯，提醒民眾除了關注心血管健康，也要重視手部神經問題。

腕隧道症候群是最常見的周邊神經壓迫疾病之一，主要是因為手腕內的「正中神經」受到壓迫所導致。患者常會出現手麻、刺痛、灼熱感、夜間麻醒、手部無力，甚至拿東西容易掉落等情況。症狀通常集中在拇指、食指、中指與部分無名指，嚴重時可能影響日常工作與生活品質。

許多人以為腕隧道症候群只是因為長時間使用電腦、滑手機或重複手部動作造成，但其實代謝疾病也是重要危險因子。根據統合分析研究顯示，高膽固醇患者發生腕隧道症候群的風險約增加2.5倍，而且在50歲以上族群及肥胖者身上風險更加明顯。

那麼，高膽固醇為何會影響手部神經呢？

研究指出，高膽固醇會造成慢性發炎反應與血管硬化。當血液中的低密度膽固醇（LDL）過高時，容易堆積在血管內壁，形成動脈粥樣硬化，使血液循環變差。當供應神經的微小血管受到影響時，神經便可能因缺血與缺氧而變得脆弱，更容易受到壓迫。

此外，高膽固醇引發的慢性發炎也可能增加腕隧道內組織腫脹，使隧道空間變窄，進一步壓迫正中神經。若同時合併糖尿病、高血壓、肥胖或代謝症候群，神經受損風險會更高。

常見腕隧道症候群症狀包括：

• 手指麻木、刺痛感

• 半夜手麻醒來

• 手腕痠痛延伸至前臂

• 手部無力、抓握困難

• 長時間打字或滑手機後症狀加重

若症狀持續超過數週，建議及早就醫，由醫師進行神經學檢查或神經傳導檢測，以避免神經長期受損。

想降低腕隧道症候群風險，除了避免過度使用手腕，更重要的是控制膽固醇與改善生活習慣，包括：

1. 定期健康檢查，追蹤膽固醇與血脂數值

2. 減少高油脂、油炸及精緻糖類攝取

3. 增加蔬菜、水果與高纖飲食

4. 維持每週規律運動習慣

5. 控制體重與腰圍

6. 避免長時間固定姿勢與重複手腕動作

7. 有慢性病者應規律服藥與追蹤

部分研究也發現，適當的降血脂治療除了保護心血管，可能也有助於減少神經發炎與壓迫風險。不過是否能直接改善腕隧道症候群，仍需更多研究證實。

總結來說，高膽固醇不只是「血管問題」，也可能影響神經健康。若本身已有高膽固醇、肥胖或代謝症候群，又經常出現手麻或手部無力症狀，應提高警覺並及早評估。透過健康飲食、規律運動與良好慢性病控制，不僅能保護心臟，也能降低腕隧道症候群等神經疾病風險，維持良好的生活品質。

參考文獻

1. Ahmad, M., & Umer, M. (2019). "Association of hypercholesterolemia with carpal tunnel syndrome: A review of the literature." Journal of Neurological Research,13(2): 123-130.

2. Brown, J. D., & Smith, R. A. (2020). "The role of lipid metabolism in peripheral neuropathy: Implications for carpal tunnel syndrome." Neuroscience and BiomedicalResearch, 27(3): 145-152.

3. Chang, W. H., & Lee, J. Y. (2018). "Hypercholesterolemia and its relationship with carpal tunnel syndrome in the aging population." International Journal of Geriatric Health, 10(4): 200-209.

4. Davis, L. J., & Johnson, S. P. (2021). "Acohort study on the correlation between cholesterol levels and the development of carpal tunnel syndrome." Clinical Research in Hand Surgery, 34(1): 88-95.

5. Ferguson, R., & Robertson, T. (2017)."Investigating the link between systemic metabolic disorders and carpal tunnel syndrome: A meta-analysis." Metabolic Disorders Journal, 22(5): 309-315.

6. Gupta, R. K., & Chauhan, V. (2020). "Inflammatory mediators in hypercholesterolemia and their role in carpal tunnel syndrome pathogenesis." Journal of In flammation Research, 7(3): 198-210.

7. Hernandez, M. J., & Lopez, P. A. (2016)."The impact of cholesterol on peripheral nerve health and function: Considerations for carpal tunnel syndrome." Neurological Sciences, 19(6): 402-410.

8. Jackson, A. B., & Williams, H. (2019). "Aretrospective analysis of lipid profiles in patients with carpal tunnel syndrome."Journal of Clinical Metabolism, 15(2):170-175.

9. Kim, S. H., & Park, S. J. (2021). "Carpal tunnel syndrome in patients with hyper lipidemia: An epidemiological study." Korean Journal of Medical Science, 36(12): 中華職業醫學雜誌 32(3)：211-220, 2025 217 1349-1356.

10. Li, C., & Zhang, R. (2018). "Association between dyslipidemia and carpal tunnel syndrome: Evidence from a population-based study." Lipids in Health and Disease, 17(1): 59-65.

11. Martin, T. A., & Zhao, Y. (2017). "An observational study of the relationship between cholesterol levels and peripheral neuropathies." Ortho-Neuro Journal, 11(4):300-307.

12. Nguyen, Q. D., & Tran, A. M. (2019)."Cholesterol-lowering interventions and their effe腕隧道症候群 on carpal tunnel syndrome symptoms." Therapeutic Advances in Musculoskeletal Disease, 11(6):312-320.

13. O’Neill, J. E., & Blake, P. R. (2020). "The prevalence of carpal tunnel syndrome in patients with hypercholesterolemia: Case-control study results." Journal of Hand Surgery, 25(3): 280-287.

14. Patel, D. M., & Singh, K. B. (2021). "Im plications of metabolic syndrome in the development of carpal tunnel syndrome." Journal of Endocrine and Metabolic Disorders, 15(7): 564-573.

15. Qureshi, A. H., & Aslam, N. (2018). "Exploring the connection between lipid abnormalities and peripheral neuropathies in diabetic and nondiabetic populations." Diabetes and Metabolic Syndrome: Clinical Research & Reviews, 12(4): 493-499.

16. Roberts, L. J., & Kenney, P. (2017). "Systematic review of the evidence linking hypercholesterolemia to carpal tunnel syndrome." Evidence-Based Neurology, 19(1):95-102.

17. Singh, R., & Kaur, J. (2020). "Longitudinal study of lipid profiles and carpal tunnel syndrome occurrence." Asian Journal of Medical Sciences, 9(3): 235-242.

18. Taylor, H. W., & Morris, L. (2019). "Peripheral vascular implications of hyper cholesterolemia and relevance to carpal tunnel syndrome." Vascular Health Management, 15(2): 225-231.

19. Ullah, F., & Mehmood, S. (2021). "Lipid-lowering treatments and their impact on neurocompression syndromes." Journal of Lipid Research, 62(8): 100045.

20. Vincent, G., & Dubois, H. (2018). "A clinical perspective on hyperlipidemia in orthopedic conditions." Journal of Orthopedic Research, 23(2): 210-217.

21. Wang, J., & He, Y. (2020). "Chronic in flammation and its role in carpal tunnel syndrome: A biochemical perspective." Biomedicine & Pharmacotherapy,32:103896.

22. Xu, F., & Li, W. (2019). "Dyslipidemia and nerve entrapment syndromes in clinical practice." Journal of Clinical Neurology, 15(5): 510-517.

23. Yang, M., & Hong, S. (2020). "A comprehensive review of metabolic syndrome and its relationship with neuropathic conditions." Metabolic Syndrome and Related Disorders, 18(3): 145-157.

24. Zhang, G., & Liu, X. (2021). "Hormonal and metabolic risk factors for peripheral neuropathy." Journal of Endocrinology, 50(5): 789-799.

25. Zhao, L., & Wang, P. (2020). "The effe腕隧道症候群 of elevated cholesterol on nerve tissue physiology and pathology."Journal of Physiology and Biochemistry, 76(4): 533-548.

26. Grundy, S. M. (2016). "Inflammation, hypertension, and the metabolic syndrome." Chinese J Occup Med 218 Journal of Clinical Hypertension, 8(6):311-316.

27. Libby, P., Ridker, P. M., & Maseri, A. (2002). "Inflammation and atherosclerosis." Circulation, 105(9): 1135-1143.

28.Freeman, M. R., & DiDonato, G. C. (2019)."Use of lipid-lowering drugs to reduce neurological disease burden." Nature Reviews Neurology, 15(6): 320-332.

29. Jenkins, A. J., Rowley, K. G., & Best, J. D.(2004). "Lipid, lipoproteins and inflammatory markers in Type 1 diabetes mellitus: relationship with microvascular and macrovascular complications."Diabetologia, 47(2): 195-205.

30. Sampson, U. K., Fazio, S., & Linton, M. F.(2012). "Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, mechanisms, and implications." Current Atherosclerosis Reports, 14(1): 1-10.

31. Kuklina, E. V., & Carroll, M. D. (2017)."Prevalence of High Low-Density Lipoprotein Cholesterol Among Adults in the United States." Journal of the American Medical Association, 302(22): 2484-2489.

32. Cohn, J. N. (2010). "The prevention and management of cardiovascular disease." The New England Journal of Medicine, 362(24): 2409-2411.

33. Boulanger, L., Zhao, Y., & Shi, H. (2007)."Predictors of acute exacerbations in patients with COPD." Chest, 132(1): 48-54.

34. Berenson, G. S., Srinivasan, S. R., & Bao, W. H. (1998). "Association between multiple cardiovascular risk factors and athero sclerosis in children and young adults."The New England Journal of Medicine, 338(23): 1650-1656.

35.Stamler, J., Wentworth, D., & Neaton, J. D.(1986). "Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor In tervention Trial (MRFIT)." Journal of the American Medical Association, 256(20): 2823-2828.

36. Assmann, G., & Schulte, H. (1988). "The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyper lipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease." American Heart Journal, 116(6 Pt 2): 1713-1724.

37. Toth, P. P., Ballantyne, C. M., & Hanson, M. E. (2008). "Clinical and economic benefits of statin therapy in a managed-care organization: a REAL-COM study." Journal of Clinical Lipidology, 2(2): 121-130.